Human Complement C3 ELISA Kit (ab108822)
Key features and details
- Sensitivity: 994 µg/ml
- Range: 1 µg/ml - 5 µg/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Competitive
- Reacts with: Human
製品の概要
-
製品名
Human Complement C3 ELISA Kit
C3/C3b キット 製品一覧 -
検出方法
Colorimetric -
再現性
Intra-Assay（同時再現性） サンプル N 平均値 SD CV% Overall 5.2% Inter-Assay（日差再現性） サンプル N 平均値 SD CV% Overall 10.2% -
サンプルの種類
Serum, Plasma -
アッセイタイプ
Competitive -
検出感度
= 994 µg/ml -
検出範囲
1 µg/ml - 5 µg/ml -
添加回収試験
105 %
-
全工程の試験時間
3h 00m -
ステップ
Multiple steps standard assay -
種交差性
交差種: Human -
製品の概要
Human Complement C3 ELISA kit is a competitive immunoassay designed for the quantitative measurement of Complement C3 in human plasma and serum.
A Complement C3 specific antibody has been precoated onto 96-well plates and blocked. Standards or test samples are added to the wells and subsequently a Complement C3 specific biotinylated detection protein is added and then followed by washing with wash buffer. Streptavidin-Peroxidase Conjugate is added and unbound conjugates are washed away with wash buffer. TMB is then used to visualize Streptavidin-Peroxidase enzymatic reaction. TMB is catalyzed by Streptavidin-Peroxidase to produce a blue color product that changes into yellow after adding acidic stop solution. The density of yellow coloration is inversely proportional to the amount of Complement C3 captured in plate.
The entire kit may be stored at -20°C for long term storage before reconstitution - Avoid repeated freeze-thaw cycles.
-
アプリケーション
適用あり: Competitive ELISAmore details -
試験プラットフォーム
Microplate
製品の特性
-
保存方法
Store at -20°C. Please refer to protocols. -
内容 1 x 96 tests 100X Streptavidin-Peroxidase Conjugate 1 x 80µl 10X Diluent M Concentrate 1 x 30ml 1X Biotinylated Human Complement C3 (Lyophilized) 1 vial 20X Wash Buffer Concentrate 1 x 30ml Chromogen Substrate 1 x 7ml Complement C3 Microplate (12 x 8 well strips) 1 unit Complement C3 Standard (Lyophilized) 1 vial Sealing Tapes 3 units Stop Solution 1 x 11ml -
研究分野
-
機能
C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. -
組織特異性
Plasma. -
関連疾患
Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:120700]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. -
配列類似性
Contains 1 anaphylatoxin-like domain.
Contains 1 NTR domain. -
翻訳後修飾
C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
Phosphorylation sites are present in the extracelllular medium. -
細胞内局在
Secreted. - Information by UniProt
-
別名
- Acylation stimulating protein cleavage product
- AHUS5
- ARMD9
see all -
参照データベース
- Entrez Gene: 718 Human
- Omim: 120700 Human
- SwissProt: P01024 Human
- Unigene: 529053 Human
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab108822の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| Competitive ELISA |
Use at an assay dependent concentration.
|
| 特記事項 |
|---|
|
Competitive ELISA
Use at an assay dependent concentration. |
画像
-
ab108822 Complement C3 Human
Compl. C3 measured in biological fluids showing quantity (micrograms) per mL of tested sample
-
Typical Standard CurveRepresentative Standard Curve using ab108822.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (15)
ab108822 は 15 報の論文で使用されています。
- Wilton DK et al. Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington's disease. Nat Med 29:2866-2884 (2023). PubMed: 37814059
- Choi YH et al. Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir. Sci Rep 12:4382 (2022). PubMed: 35288624
- Carbonaro M et al. Efficient engraftment and viral transduction of human hepatocytes in an FRG rat liver humanization model. Sci Rep 12:14079 (2022). PubMed: 35982097
- Kim D et al. Old plasma dilution reduces human biological age: a clinical study. Geroscience 44:2701-2720 (2022). PubMed: 35999337
- de Mattos Barbosa MG et al. TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells. JCI Insight 6:N/A (2021). PubMed: 34283811